| pubmed-article:7740479 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C0015491 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C1552302 | lld:lifeskim |
| pubmed-article:7740479 | lifeskim:mentions | umls-concept:C1552291 | lld:lifeskim |
| pubmed-article:7740479 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7740479 | pubmed:dateCreated | 1995-6-5 | lld:pubmed |
| pubmed-article:7740479 | pubmed:abstractText | The pharmacokinetics of intravenously administered recombinant human factor IX (rhFIX) were studied in Sprague-Dawley rats and Beagle dogs. Rats received rhFIX (50 IU/kg once daily) for 28 days, and the plasma half-life was 5 h. Anti-Human Factor IX serum antibody levels were found in only 1 of 12 rats. The pharmacokinetic profiles of rhFIX or Mononine, a purified human plasma-derived factor IX, after single 100 IU/kg i.v. doses in dogs, were similar. Peak plasma concentrations of rhFIX and Mononine were 4-5 micrograms/ml. The mean plasma half-lives were 13.2 +/- 1.6 h for rhFIX and 13.3 +/- 1.6 h for Mononine. Dogs also received rhFIX (40 IU/kg i.v., daily) for 28 days or Mononine (40 IU/kg i.v. daily) for 14 days. Anti-human Factor IX serum antibody levels were determined for each compound. Pharmacokinetic half-lives decreased in these treated dogs which developed antihuman Factor IX antibodies. The antibody responses in 28 day rhFIX (40 IU/kg) dogs were similar to 14 day Mononine (40 IU/kg) dogs. | lld:pubmed |
| pubmed-article:7740479 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7740479 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7740479 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7740479 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7740479 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7740479 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7740479 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7740479 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7740479 | pubmed:issn | 0340-6245 | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:McCarthyKK | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:SchaubR GRG | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:ApolA GAG | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:MisraBB | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:FrederickTT | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:FaulknerRR | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:RupBB | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:KeithJ CJCJr | lld:pubmed |
| pubmed-article:7740479 | pubmed:author | pubmed-author:FerrantiT JTJ | lld:pubmed |
| pubmed-article:7740479 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7740479 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:7740479 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7740479 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7740479 | pubmed:pagination | 101-5 | lld:pubmed |
| pubmed-article:7740479 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:meshHeading | pubmed-meshheading:7740479-... | lld:pubmed |
| pubmed-article:7740479 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7740479 | pubmed:articleTitle | Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. | lld:pubmed |
| pubmed-article:7740479 | pubmed:affiliation | Department of Preclinical Research, Genetics Institute, Inc., Cambridge, MA 02140, USA. | lld:pubmed |
| pubmed-article:7740479 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7740479 | pubmed:publicationType | Comparative Study | lld:pubmed |
